2022 MIPS Measure # 462: Bone density evaluation for patients with prostate cancer and receiving androgen deprivation therapy


Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT.

Initial Population

Male patients with a qualifying encounter in the measurement period AND with a diagnosis of prostate cancer AND with an order for ADT or an active medication of ADT with an intent for treatment greater than or equal to 12 months during the measurement period


Equals Initial Population

Denominator Exclusions



Patients with a bone density evaluation within the two years prior to the start of or less than three months after the start of ADT treatment

Numerator Exclusions

Not Applicable

Denominator Exceptions

Patient refused recommendation for a bone density evaluation after the start of ADT therapy


CMS-Endocrinology-2022, CMS-Oncology-2022, CMS-Urology-2022, General Oncology-2022, Hematology-Oncology, Quality-2022, Urology